Replies to post #6248 on International Stem Cell Corp. (ISCO)

[thefamilyman]

Good stuff! I particularly liked this statement. "We look forward to preliminary clinical data in Q4 2016."

CARLSBAD, CA--(Marketwired - March 07, 2016) - International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it is enrolling patients in the Phase I trial of ISC-hpNSC(R) , human parthenogenetic stem cell-derived neural stem cells for the treatment of moderate to severe Parkinson's disease. The Melbourne Health Human Research Ethics Committee (HREC) granted its approval of the Phase I clinical trial in patients with moderate to severe Parkinson's disease. This approval clears the study's initiation at the Royal Melbourne Hospital. Parkinson's disease has no cure and is the second most common neurodegenerative disease affecting over 7 million people worldwide.

Russell Kern, PhD, executive vice president and chief scientific officer of ISCO, said, "Enrollment in this trial is an important milestone. Promising preclinical results support our expectation that ISC-hpNSC will bring a long-needed solution for patients suffering from Parkinson's disease. The ability of our approach to replace and protect dopaminergic neurons and restore neural function offers significant potential benefit to patients. We look forward to preliminary clinical data in Q4 2016."

About the clinical study

The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC(R) , intracranialy transplanted into patients with moderate to severe Parkinson's disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC(R) . PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC(R) will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales.

[locksflooring]

JUST ANOTHER FLUFF TO SELL MORE SHARES OF ISCO'S CRAP STOCK!